Phynova Group

www.phynova.com TICKER: PYN     EXCHANGE:

Phynova Group is a Sino-Western private company focused on the development of botanically based therapeutics for health and personal care. The botanical compounds used in traditional Chinese medicine go through a 'westernised' IP, pre and clinical development process before being commercialised. Two drug candidates are in Phase ll clinical development: Melokinex for post-operative temporary impairment of the gastro-intestinal function especially after abdominal surgery; and PYN17 for the relief of the symptoms of chronic Hep C. Three other compounds are in pre-clinical development: PYN18 (symptoms of dengue fever), PYN22 (obesity and non-fatty liver disease), Phytoback (topical product against MRSA). Consumer and personal care products include: Relivergen (supplement for liver health), InoNorm (blood-glucose control), FatigueFix (relief of fatigue and improvement of sleep) and PhynoRadiance for skin lightening, are at an early development stage.

LATEST REPORTS

 
Review of Progress
Published: Apr 10 2008

Structure of both the operations and the organisation strengthened

Drug development program moving forward on track

£1.4m cash at year end, bolstered by subsequent equity placement

Subject to financing, Group's potential not reflected in current share levels

 
A discovery engine for Botanical drugs
Published: Jun 14 2007

  • Plant-derived medicines (Botanical Drugs) now embraced by FDA
  • Efficacy and safety concerns reduced through historic use in China
  • Current valuation reflects lack of understanding in new approach: shares can double as awareness grows

ARCHIVE